Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

Cancer Issues Author: Staff Editor Last Updated: Feb 25, 2014 - 1:49:34 PM

Robotic-Assisted Prostate Surgery Offers Better Cancer Control

By Staff Editor
Feb 25, 2014 - 1:46:28 PM

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust

Email this article
 Printer friendly page

( - An observational study from UCLA's Jonsson Comprehensive Cancer comparing robotic-assisted prostate surgery to open surgery for prostate cancer found that patients who had robotic surgery had fewer instances of cancer cells at the edge of the surgical specimen, or fewer positive margins, and less need of additional cancer treatments, such as hormone therapy or radiation, than patients who had open surgery.

Led by Dr. Jim Hu, Associate Professor and Henry E. Singleton Chair in Urology and director of robotic and minimally invasive surgery, the study was published online ahead of press in the journal European Urology.

Although it is becoming more popular, robotic-assisted radical prostatectomy (RARP)-the complete removal of the prostate using a robotic apparatus -has remained controversial because there was little evidence of better cancer control over open radical prostatectomy (ORP), the traditional surgical approach, which is also less costly.

In an effort to determine whether or not robotic surgery offered an advantage, Hu and colleagues conducted a retrospective study comparing 5,556 patients who received RARP to 7,878 who received ORP during the years 2004 and 2009. Data was provided by the Surveillance, Epidemiology, and End Results (SEER)-Medicare, program of cancer registries that collect clinical and demographic information for persons with cancer.

The researchers compared the two groups by surgical margin status, which is the amount of cancer cells at the edge of the prostate specimen. A positive margin may result from cutting through the cancer and leaving some cancer behind, rather than cutting around the cancer completely. A positive margin for prostate cancer has been shown to lead to a greater risk of prostate cancer recurrence and death from the disease. Hu and colleagues also assessed the use of additional cancer therapy (androgen deprivation, or hormone therapy, and radiation) after robotic versus open surgery.

They found that RARP was associated with 5 percent fewer positive surgical margins (those that tested positive for the presence of cancer), 13.6 percent versus 18.3 percent for ORP, and this difference was greater for patients with intermediate- and high-risk prostate cancer. Patients who had robotic surgery also had a one-third reduction in likelihood of using additional cancer therapy within 24 months after robotic surgery compared to open surgery.

These findings show that despite a greater upfront cost of robotic surgery, the fewer positive surgical margins and less need for radiation therapy after robotic surgery may translate into less downstream costs and side effects of radiation and hormone therapy.

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2013, the Jonsson Cancer Center was named among the top 12 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 14 consecutive years. For more information on the Jonsson Cancer Center, visit our website at


For advertising and promotion on, call Mike McCurdy: 877-634-9180 or [email protected] We have over 7,000 journalists as subscribers.


Top of Page

Cancer Issues
Latest Headlines

+ Neuro-oncologists Discover Cancer Cells Can Burn Acetate for Fuel
+ New Year’s Resolution from The Skin Cancer Foundation: DON’T TAN
+ ‘Sugar-Coated’ Microcapsule Eliminates Toxic Punch of Experimental Anti-Cancer Drug
+ A New Strategy for Developing Drugs to Fight Cancer and Other Diseases
+ Bacterial 'Bunches' Linked to Some Colorectal Cancers
+ Signaling Mechanism Could be Target for Survival, Growth of Tumor Cells in Brain Cancer
+ FDA Approves Drug that Extends Survival in the Most Common Type of Lung Cancer
+ Testosterone May Contribute to Colon Cancer Tumor Growth
+ New Drug Combination for Advanced Breast Cancer Delays Disease Progression
+ Toughest Breast Cancer May Have Met Its Match

Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions